Upon joining the trial, the patient will be informed about the study’s purpose, which is to investigate if a single dose of levosimendan given during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest increases 30-day survival compared to a placebo.

The patient will be randomly assigned to receive either the levosimendan or a placebo during the trial.

During the trial, the patient will receive a single dose of levosimendan or a placebo through an intravenous injection. This means the medication will be delivered directly into the bloodstream through a vein.

The medication used is called Simdax 2.5 mg/ml, which is a solution for infusion.

After the administration of the medication, the patient’s condition will be closely monitored to assess the effects of the treatment.

The primary goal is to determine survival at day 30 after the cardiac arrest event.

Secondary observations include the return of spontaneous circulation, transport to the hospital, and the patient’s condition upon arrival at the hospital.

If the patient is admitted to the ICU, further monitoring will occur for up to 72 hours. This includes checking the number and duration of any additional medications needed to support heart function.

The patient’s overall organ function and neurological outcomes will also be evaluated during this period.

The trial participation concludes with the assessment of the patient’s condition at the end of the observation period.

The final evaluation will include the patient’s survival status, any organ dysfunction, and neurological outcomes at discharge.